New malaria vaccine candidate tested in UK volunteers
NCT ID NCT05270265
First seen Jan 16, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This early-stage study tested a new vaccine against Plasmodium vivax malaria in 25 healthy adults in the UK. The vaccine, Pvs25-IMX313 with Matrix-M1 adjuvant, was given to see if it is safe and triggers an immune response. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA VIVAX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CCVTM, University of Oxford, Churchill Hospital
Oxford, OX3 7LE, United Kingdom
Conditions
Explore the condition pages connected to this study.